Literature DB >> 8292466

A multicentre study of the safety and efficacy of amlodipine in mild to moderate hypertension.

B W Cross1, M G Kirby, S Miller, S Shah, D M Sheldon, M T Sweeney.   

Abstract

An open, non-comparative study of 10 weeks' duration was conducted in general practice to assess the safety of amlodipine in patients with mild to moderate hypertension. Of the 5352 patients entering the study, 5135 received amlodipine; 4621 patients (90%) with a mean age of 58.2 years completed the study. Normalisation of blood pressure was achieved in over 80% of patients with a mean reduction of 21/15 mmHg. The mean final dose of amlodipine was 6.8 mg/day. Adverse experiences possibly related to amlodipine were reported by 19.3% of patients, and overall adverse events led to withdrawal in 6.7% of patients. The most common reported side-effect was oedema. The frequency of headache was almost identical in older and younger patients and oedema, flushing and dizziness were seen only slightly more often in elderly patients. Ninety per cent of patients were considered by their GP to have shown excellent or good toleration of therapy. Over 85% of patients elected to continue on amlodipine therapy after completion of the study.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8292466

Source DB:  PubMed          Journal:  Br J Clin Pract        ISSN: 0007-0947


  7 in total

1.  Enzyme linked immunosorbent assay for determination of amlodipine in plasma.

Authors:  K Matalka; T El-Thaher; M Saleem; T Arafat; A Jehanli; A Badwan
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

2.  Efficacy and safety of amlodipine: a comparative study of hypertensive patients treated at primary- and specialised-care centres.

Authors:  Y Valcárcel; R Jiménez; V Hernández; R Arístegui; A Gil
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

Review 3.  Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease.

Authors:  M Haria; A J Wagstaff
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

4.  Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects.

Authors:  C Kollmannsberger; D Soulieres; R Wong; A Scalera; R Gaspo; G Bjarnason
Journal:  Can Urol Assoc J       Date:  2007-06       Impact factor: 1.862

5.  Efficacy, safety, and palatability of RACTAB(®) formulation amlodipine orally disintegrating tablets.

Authors:  Mari Fukui-Soubou; Hirotaka Terashima; Kiyoshi Kawashima; Osamu Utsunomiya; Taichiroh Terada
Journal:  Drugs R D       Date:  2011-12-01

6.  Incremental Blood Pressure-Lowering Effect of Titrating Amlodipine for the Treatment of Hypertension in Patients Including Those Aged ≥55 Years.

Authors:  Barrett W Jeffers; Rahul Bhambri; Jeffery Robbins
Journal:  Am J Ther       Date:  2015 Jul-Aug       Impact factor: 2.688

Review 7.  Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer.

Authors:  Nathalie Theou-Anton; Sandrine Faivre; Chantal Dreyer; Eric Raymond
Journal:  Drug Saf       Date:  2009       Impact factor: 5.228

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.